Rizzuto lab

@pregnancyimmunolab.bsky.social

Studying fetomaternal tolerance since 2022 at Memorial Sloan Kettering Cancer Center. http://therizzutolab.com

Congratulations @jcstark.bsky.social and the team, antibody-lectin chimeras (AbLecs), a new modality for cancer immune therapy, now published @natbiotech.nature.com. These bispecifics can block glyco-immune checkpoint receptor ligands directly at the immune synapse/activate immune effector functions

Nature Biotechnology@natbiotech.nature.com · 10mo ago

Antibody-lectin chimeras for glyco-immune checkpoint blockade - @jcstark.bsky.social @carolynbertozzi.bskyverified.social go.nature.com/4aRDpk8

🚀 NY-CURES Launch — Championing State-Wide Investment in Science! 🚀 Our new coalition advocates for sustained public support of New York’s vibrant biomedical research ecosystem — creating cures, economic gains & strengthening communities. Sign up. Stay informed. Join the movement: www.nycures.org/

Bild